The Joint Corp. (United States)

The Joint Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 7.69, reflecting a challenging year with a 46.98% decline in stock price. The company has a market cap of USD 164 million and shows negative financial metrics, including a return on equity of -13.76%.

The Joint Corp. has reached a new 52-week low, reflecting a challenging year with a significant performance decline. Despite a reported profit increase, the company's financial metrics indicate a complex structure, including a negative return on equity and a high price-to-book ratio, contributing to its current market position.

The Joint Corp. has reached a new 52-week low of USD 7.78, reflecting a challenging year with a 46.98% decline from its high of USD 13.47. Despite a 44.8% increase in profits, the company has struggled with negative stock performance and underperformed against the S&P 500.

The Joint Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. With a market capitalization of USD 164 million, the company faces financial challenges, including a negative return on equity and a high price-to-book ratio, indicating ongoing difficulties in the market.

The Joint Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of USD 8.67 as of October 7, 2025. The company has a market cap of USD 164 million and operates at a loss, with significant financial challenges reflected in its ratios and stock performance.

The Joint Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low, reflecting a 40.66% decline over the past year. With a market cap of USD 164 million, the company faces financial challenges, including negative earnings and a high price-to-book ratio.

The Joint Corp. has reached a new 52-week low of USD 8.93, reflecting a significant decline in its stock price, which has dropped by nearly 39% over the past year. Despite a 44.8% increase in profits, the company continues to face challenges in the market.

The Joint Corp. has reached a new 52-week low, reflecting a significant decline in its stock price over the past year, contrasting with the S&P 500's gains. The company operates at a loss, with a high price-to-book ratio and negative return on equity, indicating financial challenges despite increased profits.

The Joint Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has hit a new 52-week low of USD 9.53, reflecting a 35.89% decline over the past year. With a market cap of USD 164 million, the company faces financial challenges, including a negative return on equity and no positive P/E ratio.